A panel of total 39 cell lines from different tumor systems (breast, ovarian, gastric, head and neck, sarcoma, etc.)was characterized for their HER2 expression level by flow cytometry and CTL activity (Table 1). This evidence concerns the gene ERBB2 and sarcoma.